{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:30:36Z","timestamp":1790541036384,"version":"4.1.0"},"reference-count":187,"publisher":"Tsinghua University Press","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.26599\/nr.2025.94907534","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T06:53:38Z","timestamp":1746514418000},"page":"94907534","source":"Crossref","is-referenced-by-count":2,"title":["Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines"],"prefix":"10.26599","volume":"18","author":[{"given":"Mengwen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11138","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: Advancements, challenges and prospects","volume":"8","author":"T. Fan","year":"2023","unstructured":"T. Fan. Therapeutic cancer vaccines: Advancements, challenges and prospects. 2023, 8: 450.","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/toxins12040241","article-title":"Jr","volume":"12","author":"R. D. Carlson","year":"2020","unstructured":"R. D. Carlson. Jr. 2020, 12: 241.","journal-title":"; Snook, A. E. Talkin\u2019 toxins: From Coley\u2019s to modern cancer immunotherapy. Toxins"},{"key":"ref3","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"E. F. McCarthy","year":"2006","unstructured":"E. F. McCarthy. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. 2006, 26: 154-158.","journal-title":"Iowa Orthop. J."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: Progress, opportunities and challenges","volume":"17","author":"J. D. Martin","year":"2020","unstructured":"J. D. Martin. Improving cancer immunotherapy using nanomedicines: Progress, opportunities and challenges. 2020, 17: 251-266.","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e13025","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: Current trends in clinical application","volume":"54","author":"W. S. Liu","year":"2021","unstructured":"W. S. Liu. Peptide-based therapeutic cancer vaccine: Current trends in clinical application. 2021, 54: e13025.","journal-title":"Cell Prolif."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"D. B. Johnson","year":"2022","unstructured":"D. B. Johnson. Immune-checkpoint inhibitors: Long-term implications of toxicity. 2022, 19: 254-267.","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for CAR-T therapy","volume":"12","author":"J. S. Wei","year":"2019","unstructured":"J. S. Wei. Target selection for CAR-T therapy. 2019, 12: 62.","journal-title":"J. Hematol. Oncol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"R. E. Kontermann","year":"2012","unstructured":"R. E. Kontermann. Dual targeting strategies with bispecific antibodies. 2012, 4: 182-197.","journal-title":"MAbs"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"M. Saxena","year":"2021","unstructured":"M. Saxena. Therapeutic cancer vaccines. 2021, 21: 360-378.","journal-title":"Nat. Rev. Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1210044","DOI":"10.3389\/fimmu.2023.1210044","article-title":"Peptide-based vaccine for cancer therapies","volume":"14","author":"L. Buonaguro","year":"2023","unstructured":"L. Buonaguro. Peptide-based vaccine for cancer therapies. 2023, 14: 1210044.","journal-title":"Front. Immunol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.ctrv.2022.102429","article-title":"Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials","volume":"109","author":"N. Sobhani","year":"2022","unstructured":"N. Sobhani. Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. 2022, 109: 102429.","journal-title":"Cancer Treat. Rev."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.0105-2896.2004.00198.x","article-title":"The development of effector and memory T cells in cutaneous leishmaniasis: The implications for vaccine development","volume":"201","author":"P. Scott","year":"2004","unstructured":"P. Scott. The development of effector and memory T cells in cutaneous leishmaniasis: The implications for vaccine development. 2004, 201: 318-338.","journal-title":"Immunol. Rev."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-016-0160-y","article-title":"Adjuvants for peptide-based cancer vaccines","volume":"4","author":"H. Khong","year":"2016","unstructured":"H. Khong. Adjuvants for peptide-based cancer vaccines. 2016, 4: 56.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-10811-3_25","author":"","unstructured":"","journal-title":"null"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"9749363","DOI":"10.1155\/2022\/9749363","article-title":"Development of peptide-based vaccines for cancer","volume":"2022","author":"N. Abd-Aziz","year":"2022","unstructured":"N. Abd-Aziz. Development of peptide-based vaccines for cancer. 2022, 2022: 9749363.","journal-title":"J. Oncol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"B72","DOI":"10.1016\/j.vaccine.2007.06.043","article-title":"Enhancing cancer vaccines with immunomodulators","volume":"25","author":"N. L. Berinstein","year":"2007","unstructured":"N. L. Berinstein. Enhancing cancer vaccines with immunomodulators. 2007, 25: B72-B88.","journal-title":"Vaccine"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41698-023-00364-1","article-title":"Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer","volume":"7","author":"C. Rolfo","year":"2023","unstructured":"C. Rolfo. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer. 2023, 7: 26.","journal-title":"npj Precis. Oncol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: Mechanisms and platforms","volume":"8","author":"T. M. Zhao","year":"2023","unstructured":"T. M. Zhao. Vaccine adjuvants: Mechanisms and platforms. 2023, 8: 283.","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e004709","DOI":"10.1136\/jitc-2022-004709","article-title":"Peptide emulsions in incomplete Freund\u2019s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer","volume":"10","author":"M. M. Melssen","year":"2022","unstructured":"M. M. Melssen. Peptide emulsions in incomplete Freund\u2019s adjuvant create effective nurseries promoting egress of systemic CD4\n              + and CD8\n              + T cells for immunotherapy of cancer. 2022, 10: e004709.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref20","first-page":"2756","article-title":"Phase I trial of a MART-1 peptide vaccine with incomplete Freund\u2019s adjuvant for resected high-risk melanoma","volume":"5","author":"F. Wang","year":"1999","unstructured":"F. Wang. Phase I trial of a MART-1 peptide vaccine with incomplete Freund\u2019s adjuvant for resected high-risk melanoma. 1999, 5: 2756-2765.","journal-title":"Clin. Cancer Res."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jconrel.2022.07.036","article-title":"Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches","volume":"349","author":"F. Davodabadi","year":"2022","unstructured":"F. Davodabadi. Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. 2022, 349: 844-875.","journal-title":"J. Control. Release"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2147\/IJN.S269986","article-title":"Peptide-based nanovaccines in the treatment of cervical cancer: A review of recent advances","volume":"17","author":"J. H. Zhang","year":"2022","unstructured":"J. H. Zhang. Peptide-based nanovaccines in the treatment of cervical cancer: A review of recent advances. 2022, 17: 869-900.","journal-title":"Int. J. Nanomed."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/jco.2009.27.15_suppl.3002","article-title":"Comparison of the immunogenicity of Montanide ISA 51 adjuvant and cytokine-matured dendritic cells in a randomized controlled clinical trial of melanoma vaccines","volume":"27","author":"D. W. O'Neill","year":"2009","unstructured":"D. W. O'Neill. Comparison of the immunogenicity of Montanide ISA 51 adjuvant and cytokine-matured dendritic cells in a randomized controlled clinical trial of melanoma vaccines. 2009, 27: 3002.","journal-title":"J. Clin. Oncol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1200\/jco.2005.23.16_suppl.2506","article-title":"Randomized phase II trial of melanoma peptides with Montanide ISA 51 and different doses of IL-12 with Alum for resected stages IIC\/III and IV melanoma","volume":"23","author":"J. S. Weber","year":"2005","unstructured":"J. S. Weber. Randomized phase II trial of melanoma peptides with Montanide ISA 51 and different doses of IL-12 with Alum for resected stages IIC\/III and IV melanoma. 2005, 23: 2506.","journal-title":"J. Clin. Oncol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1039\/D3TB02861E","article-title":"Vaccine adjuvants: Current status, research and development, licensing, and future opportunities","volume":"12","author":"Y. Cui","year":"2024","unstructured":"Y. Cui. Vaccine adjuvants: Current status, research and development, licensing, and future opportunities. 2024, 12: 4118-4137.","journal-title":"J. Mater. Chem. B"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e24662","DOI":"10.1016\/j.heliyon.2024.e24662","article-title":"Research progress on emulsion vaccine adjuvants","volume":"10","author":"Z. Q. Huang","year":"2024","unstructured":"Z. Q. Huang. Research progress on emulsion vaccine adjuvants. 2024, 10: e24662.","journal-title":"Heliyon"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e000544","DOI":"10.1136\/jitc-2020-000544","article-title":"Incomplete Freund\u2019s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment","volume":"8","author":"K. E. Pollack","year":"2020","unstructured":"K. E. Pollack. Incomplete Freund\u2019s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. 2020, 8: e000544.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fimmu.2017.00269","article-title":"CIMAvax-EGF: A new therapeutic vaccine for advanced non-small cell lung cancer patients","volume":"8","author":"D. Saavedra","year":"2017","unstructured":"D. Saavedra. CIMAvax-EGF: A new therapeutic vaccine for advanced non-small cell lung cancer patients. 2017, 8: 269.","journal-title":"Front. Immunol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"M. S. Ahluwalia","year":"2023","unstructured":"M. S. Ahluwalia. Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma. 2023, 41: 1453-1465.","journal-title":"J. Clin. Oncol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"D. Y. Li","year":"2021","unstructured":"D. Y. Li. Pattern recognition receptors in health and diseases. 2021, 6: 291.","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors","volume":"11","author":"T. Kawai","year":"2010","unstructured":"T. Kawai. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. 2010, 11: 373-384.","journal-title":"Nat. Immunol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.mtnano.2019.100029","article-title":"Leveraging biomaterials for cancer immunotherapy: Targeting pattern recognition receptors","volume":"5","author":"W. Song","year":"2019","unstructured":"W. Song. Leveraging biomaterials for cancer immunotherapy: Targeting pattern recognition receptors. 2019, 5: 100029.","journal-title":"Mater. Today Nano."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/0974-2077.184040","article-title":"Facial basal cell carcinoma treated with topical 5% Imiquimod cream with dermoscopic evaluation","volume":"9","author":"A. Singal","year":"2016","unstructured":"A. Singal. Facial basal cell carcinoma treated with topical 5% Imiquimod cream with dermoscopic evaluation. 2016, 9: 122-125.","journal-title":"J. Cutan. Aesthet. Surg."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41565-022-01296-w","article-title":"A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion","volume":"18","author":"S. M. Jin","year":"2023","unstructured":"S. M. Jin. A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion. 2023, 18: 390-402.","journal-title":"Nat. Nanotechnol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/CM9.0000000000002181","article-title":"Neoantigens in precision cancer immunotherapy: From identification to clinical applications","volume":"135","author":"Q. Zhang","year":"2022","unstructured":"Q. Zhang. Neoantigens in precision cancer immunotherapy: From identification to clinical applications. 2022, 135: 1285-1298.","journal-title":"Chin. Med. J."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s40425-017-0295-5","article-title":"A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer","volume":"5","author":"P. M. Dillon","year":"2017","unstructured":"P. M. Dillon. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. 2017, 5: 92.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40425-019-0625-x","article-title":"A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund\u2019s adjuvant in melanoma patients","volume":"7","author":"M. M. Melssen","year":"2019","unstructured":"M. M. Melssen. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund\u2019s adjuvant in melanoma patients. 2019, 7: 163.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.apsb.2023.12.010","article-title":"Small-molecule agents for cancer immunotherapy","volume":"14","author":"F. Wang","year":"2024","unstructured":"F. Wang. Small-molecule agents for cancer immunotherapy. 2024, 14: 905-952.","journal-title":"Acta Pharm. Sin. B"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/med.21553","article-title":"Recent clinical trends in Toll-like receptor targeting therapeutics","volume":"39","author":"M. A. Anwar","year":"2019","unstructured":"M. A. Anwar. Recent clinical trends in Toll-like receptor targeting therapeutics. 2019, 39: 1053-1090.","journal-title":"Med. Res. Rev."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1111\/j.1349-7006.2010.01732.x","article-title":"Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma","volume":"101","author":"M. Iwahashi","year":"2010","unstructured":"M. Iwahashi. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. 2010, 101: 2510-2517.","journal-title":"Cancer Sci."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e005952","DOI":"10.1136\/jitc-2022-005952","article-title":"Intratumoral IFN-\u03b3 or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine","volume":"11","author":"C. A. Tran","year":"2023","unstructured":"C. A. Tran. Intratumoral IFN-\u03b3 or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine. 2023, 11: e005952.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3390\/pharmaceutics14102076","article-title":"Topically applied resiquimod versus imiquimod as a potential adjuvant in melanoma treatment","volume":"14","author":"S. Tambunlertchai","year":"2022","unstructured":"S. Tambunlertchai. Topically applied resiquimod versus imiquimod as a potential adjuvant in melanoma treatment. 2022, 14: 2076.","journal-title":"Pharmaceutics"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"107160","DOI":"10.1016\/j.phrs.2024.107160","article-title":"When will the Immune-Stimulating Antibody Conjugates (ISACs) be transferred from bench to bedside","volume":"203","author":"C. Fu","year":"2024","unstructured":"C. Fu. When will the Immune-Stimulating Antibody Conjugates (ISACs) be transferred from bench to bedside. 2024, 203: 107160.","journal-title":"Pharm. Res."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e15171","DOI":"10.1200\/JCO.2018.36.15_suppl.e15171","article-title":"Phase I\/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma","volume":"36","author":"S. P. Patel","year":"2018","unstructured":"S. P. Patel. Phase I\/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma. 2018, 36: e15171.","journal-title":"J. Clin. Oncol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"100637","DOI":"10.1016\/j.bj.2023.100637","article-title":"The effects of NOD-like receptors on adaptive immune responses","volume":"47","author":"B. K. Tsankov","year":"2024","unstructured":"B. K. Tsankov. The effects of NOD-like receptors on adaptive immune responses. 2024, 47: 100637.","journal-title":"Biomed. J."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"12294","DOI":"10.1073\/pnas.1400478111","article-title":"Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants","volume":"111","author":"C. Maisonneuve","year":"2014","unstructured":"C. Maisonneuve. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. 2014, 111: 12294-12299.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd2783","article-title":"Unleashing the therapeutic potential of NOD-like receptors","volume":"8","author":"K. Geddes","year":"2009","unstructured":"K. Geddes. Unleashing the therapeutic potential of NOD-like receptors. 2009, 8: 465-479.","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"9904","DOI":"10.1021\/acsnano.0c02765","article-title":"Co-delivery of peptide neoantigens and stimulator of interferon genes agonists enhances response to cancer vaccines","volume":"14","author":"D. Shae","year":"2020","unstructured":"D. Shae. Co-delivery of peptide neoantigens and stimulator of interferon genes agonists enhances response to cancer vaccines. 2020, 14: 9904-9916.","journal-title":"ACS Nano"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e2214278119","DOI":"10.1073\/pnas.2214278119","article-title":"Tumor-targeted delivery of a STING agonist improvescancer immunotherapy","volume":"119","author":"Y. T. Wu","year":"2022","unstructured":"Y. T. Wu. Tumor-targeted delivery of a STING agonist improvescancer immunotherapy. 2022, 119: e2214278119.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"114020","DOI":"10.1016\/j.addr.2021.114020","article-title":"Delivery of STING agonists for adjuvanting subunit vaccines","volume":"179","author":"S. Van Herck","year":"2021","unstructured":"S. Van Herck. Delivery of STING agonists for adjuvanting subunit vaccines. 2021, 179: 114020.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.3390\/molecules27144638","article-title":"Activation of stimulation of interferon genes (STING) signal and cancer immunotherapy","volume":"27","author":"K. W. Luo","year":"2022","unstructured":"K. W. Luo. Activation of stimulation of interferon genes (STING) signal and cancer immunotherapy. 2022, 27: 4638.","journal-title":"Molecules"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nnano.2017.52","article-title":"A STING-activating nanovaccine for cancer immunotherapy","volume":"12","author":"M. Luo","year":"2017","unstructured":"M. Luo. A STING-activating nanovaccine for cancer immunotherapy. 2017, 12: 648-654.","journal-title":"Nat. Nanotechnol."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"R. Hernandez","year":"2022","unstructured":"R. Hernandez. Engineering IL-2 for immunotherapy of autoimmunity and cancer. 2022, 22: 614-628.","journal-title":"Nat. Rev. Immunol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in Treg cell function","volume":"17","author":"T. Chinen","year":"2016","unstructured":"T. Chinen. An essential role for the IL-2 receptor in T\n              reg cell function. 2016, 17: 1322-1333.","journal-title":"Nat. Immunol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"104539","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"M. E. Raeber","year":"2023","unstructured":"M. E. Raeber. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. 2023, 90: 104539.","journal-title":"EBioMedicine"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1038\/emm.2016.64","article-title":"Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types","volume":"48","author":"I. S. Hong","year":"2016","unstructured":"I. S. Hong. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. 2016, 48: e242.","journal-title":"Exp. Mol. Med."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1080\/21645515.2016.1221551","article-title":"Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines","volume":"12","author":"T. W. Yu","year":"2016","unstructured":"T. W. Yu. Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines. 2016, 12: 3020-3028.","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/annonc\/mdl158","article-title":"Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients","volume":"18","author":"G. Parmiani","year":"2007","unstructured":"G. Parmiani. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. 2007, 18: 226-232.","journal-title":"Ann. Oncol."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"S. A. Rosenberg","year":"1994","unstructured":"S. A. Rosenberg. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. 1994, 271: 907-913.","journal-title":"JAMA"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-08-0116","article-title":"Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines","volume":"14","author":"F. O. Smith","year":"2008","unstructured":"F. O. Smith. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. 2008, 14: 5610-5618.","journal-title":"Clin. Cancer Res."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/ncponc0926","article-title":"Interleukin 2 for patients with renal cancer","volume":"4","author":"S. A. Rosenberg","year":"2007","unstructured":"S. A. Rosenberg. Interleukin 2 for patients with renal cancer. 2007, 4: 497.","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"901277","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: A double-edged sword in cancer immunotherapy","volume":"13","author":"A. Kumar","year":"2022","unstructured":"A. Kumar. GM-CSF: A double-edged sword in cancer immunotherapy. 2022, 13: 901277.","journal-title":"Front. Immunol."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative safety of vaccine adjuvants: A summary of current evidence and future needs","volume":"38","author":"N. Petrovsky","year":"2015","unstructured":"N. Petrovsky. Comparative safety of vaccine adjuvants: A summary of current evidence and future needs. 2015, 38: 1059-1074.","journal-title":"Drug Saf."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/15058","article-title":"Advances in vaccine adjuvants","volume":"17","author":"M. Singh","year":"1999","unstructured":"M. Singh. Advances in vaccine adjuvants. 1999, 17: 1075-1081.","journal-title":"Nat. Biotechnol."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.biopha.2018.06.026","article-title":"Efficacy and safety of immunological adjuvants. Where is the cut-off","volume":"105","author":"A. Batista-Duharte","year":"2018","unstructured":"A. Batista-Duharte. Efficacy and safety of immunological adjuvants. Where is the cut-off. 2018, 105: 616-624.","journal-title":"Biomed. Pharmacother."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"B. Pulendran","year":"2021","unstructured":"B. Pulendran. Emerging concepts in the science of vaccine adjuvants. 2021, 20: 454-475.","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41570-020-00244-3","article-title":"Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action","volume":"5","author":"C. Pifferi","year":"2021","unstructured":"C. Pifferi. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. 2021, 5: 197-216.","journal-title":"Nat. Rev. Chem."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"778","DOI":"10.4161\/hv.27332","article-title":"Recent progress in adjuvant discovery for peptide-based subunit vaccines","volume":"10","author":"F. Azmi","year":"2014","unstructured":"F. Azmi. Recent progress in adjuvant discovery for peptide-based subunit vaccines. 2014, 10: 778-796.","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: Recent progress in adjuvant research","volume":"5","author":"B. Guy","year":"2007","unstructured":"B. Guy. The perfect mix: Recent progress in adjuvant research. 2007, 5: 396-397.","journal-title":"Nat. Rev. Microbiol."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.tips.2017.06.002","article-title":"An overview of novel adjuvants designed for improving vaccine efficacy","volume":"38","author":"S. R. Bonam","year":"2017","unstructured":"S. R. Bonam. An overview of novel adjuvants designed for improving vaccine efficacy. 2017, 38: 771-793.","journal-title":"Trends Pharmacol. Sci."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"e2207841119","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response","volume":"119","author":"J. J. Chen","year":"2022","unstructured":"J. J. Chen. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8\n              + T cell response. 2022, 119: e2207841119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"113914","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Y. Y. Ding","year":"2021","unstructured":"Y. Y. Ding. Vaccine delivery systems toward lymph nodes. 2021, 179: 113914.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41565-020-0739-9","article-title":"Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health","volume":"16","author":"C. N. Fries","year":"2021","unstructured":"C. N. Fries. Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. 2021, 16: 1-14.","journal-title":"Nat. Nanotechnol."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2021.03.037","article-title":"Engineering a sustained release vaccine with a pathogen-mimicking manner for robust and durable immune responses","volume":"333","author":"Y. Y. Hou","year":"2021","unstructured":"Y. Y. Hou. Engineering a sustained release vaccine with a pathogen-mimicking manner for robust and durable immune responses. 2021, 333: 162-175.","journal-title":"J. Control. Release"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41551-020-00624-6","article-title":"Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen","volume":"5","author":"X. L. Xie","year":"2021","unstructured":"X. L. Xie. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. 2021, 5: 414-428.","journal-title":"Nat. Biomed. Eng."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"E6639","DOI":"10.1073\/pnas.1606050113","article-title":"Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination","volume":"113","author":"H. H. Tam","year":"2016","unstructured":"H. H. Tam. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. 2016, 113: E6639-E6648.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"115992","DOI":"10.1016\/j.biopha.2023.115992","article-title":"Nanovaccines: An effective therapeutic approach for cancer therapy","volume":"170","author":"S. Gurunathan","year":"2024","unstructured":"S. Gurunathan. Nanovaccines: An effective therapeutic approach for cancer therapy. 2024, 170: 115992.","journal-title":"Biomed. Pharmacother."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.nantod.2025.102691","article-title":"An all-in-one polymeric nanomedicine as in situ cascade cancer vaccine for potent cancer immunotherapy","volume":"62","author":"B. Xu","year":"2025","unstructured":"B. Xu. An all-in-one polymeric nanomedicine as \n              in situ cascade cancer vaccine for potent cancer immunotherapy. 2025, 62: 102691.","journal-title":"Nano Today"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1021\/acsnano.2c09619","article-title":"Nanovaccines fostering tertiary lymphoid structure to attack mimicry nasopharyngeal carcinoma","volume":"17","author":"Z. F. Wen","year":"2023","unstructured":"Z. F. Wen. Nanovaccines fostering tertiary lymphoid structure to attack mimicry nasopharyngeal carcinoma. 2023, 17: 7194-7206.","journal-title":"ACS Nano"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41565-022-01098-0","article-title":"A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy","volume":"17","author":"C. Liu","year":"2022","unstructured":"C. Liu. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. 2022, 17: 531-540.","journal-title":"Nat. Nanotechnol."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","article-title":"A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists","volume":"18","author":"J. J. Baljon","year":"2024","unstructured":"J. J. Baljon. A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists. 2024, 18: 6845-6862.","journal-title":"ACS Nano"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bioactmat.2023.02.016","article-title":"Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy","volume":"26","author":"T. Su","year":"2023","unstructured":"T. Su. Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. 2023, 26: 169-180.","journal-title":"Bioact. Mater."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"11691","DOI":"10.1021\/acs.jmedchem.0c00851","article-title":"Self-adjuvanting cancer vaccines from conjugation-ready lipid A analogues and synthetic long peptides","volume":"63","author":"N. R. M. Reintjens","year":"2020","unstructured":"N. R. M. Reintjens. Self-adjuvanting cancer vaccines from conjugation-ready lipid A analogues and synthetic long peptides. 2020, 63: 11691-11706.","journal-title":"J. Med. Chem."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1007\/s12274-022-5205-6","article-title":"Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer","volume":"16","author":"Y. Liu","year":"2023","unstructured":"Y. Liu. Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer. 2023, 16: 5300-5310.","journal-title":"Nano Res."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"10522","DOI":"10.1021\/acs.nanolett.3c03419","article-title":"Transmucosal delivery of nasal nanovaccines enhancing mucosal and systemic immunity","volume":"23","author":"Y. C. Xu","year":"2023","unstructured":"Y. C. Xu. Transmucosal delivery of nasal nanovaccines enhancing mucosal and systemic immunity. 2023, 23: 10522-10531.","journal-title":"Nano Lett."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"9816272","DOI":"10.34133\/2022\/9816272","article-title":"Photothermal nano-vaccine promoting antigen presentation and dendritic cells infiltration for enhanced immunotherapy of melanoma via transdermal microneedles delivery","volume":"2022","author":"J. J. Zhu","year":"2022","unstructured":"J. J. Zhu. Photothermal nano-vaccine promoting antigen presentation and dendritic cells infiltration for enhanced immunotherapy of melanoma via transdermal microneedles delivery. 2022, 2022: 9816272.","journal-title":"Research"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wnan.1354","article-title":"Adjuvants in micro-to nanoscale: Current state and future direction","volume":"8","author":"A. Gupta","year":"2016","unstructured":"A. Gupta. Adjuvants in micro-to nanoscale: Current state and future direction. 2016, 8: 61-84.","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/252252a0","article-title":"Liposomes as immunological adjuvants","volume":"252","author":"A. G. Allison","year":"1974","unstructured":"A. G. Allison. Liposomes as immunological adjuvants. 1974, 252: 252.","journal-title":"Nature"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1134\/S1990747822020076","article-title":"Liposomes as adjuvants and vaccine delivery systems","volume":"16","author":"D. S. Tretiakova","year":"2022","unstructured":"D. S. Tretiakova. Liposomes as adjuvants and vaccine delivery systems. 2022, 16: 1-20.","journal-title":"Biochem. (Mosc.) Suppl. Ser. A Membr. Cell Biol."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ijpharm.2019.03.002","article-title":"Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform","volume":"562","author":"C. Jacoberger-Foissac","year":"2019","unstructured":"C. Jacoberger-Foissac. Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform. 2019, 562: 342-350.","journal-title":"Int. J. Pharm."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","article-title":"Peptide\u2013TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","volume":"38","author":"G. M. Lynn","year":"2020","unstructured":"G. M. Lynn. Peptide\u2013TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. 2020, 38: 320-332.","journal-title":"Nat. Biotechnol."},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"G. G. Kenter","year":"2009","unstructured":"G. G. Kenter. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. 2009, 361: 1838-1847.","journal-title":"N. Engl. J. Med."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/2326-6066.CIR-16-0283","article-title":"Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines","volume":"5","author":"E. M. Varypataki","year":"2017","unstructured":"E. M. Varypataki. Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines. 2017, 5: 222-233.","journal-title":"Cancer Immunol. Res."},{"key":"ref95","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.canlet.2014.09.016","article-title":"P5 HER2\/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer","volume":"355","author":"S. Shariat","year":"2014","unstructured":"S. Shariat. P5 HER2\/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. 2014, 355: 54-60.","journal-title":"Cancer Lett."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1021\/acsnano.0c07680","article-title":"A potent cancer vaccine adjuvant system for particleization of short, synthetic CD8+ T cell epitopes","volume":"15","author":"X. D. He","year":"2021","unstructured":"X. D. He. A potent cancer vaccine adjuvant system for particleization of short, synthetic CD8\n              + T cell epitopes. 2021, 15: 4357-4371.","journal-title":"ACS Nano"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/BTT.S55196","article-title":"Therapeutic vaccines and cancer: Focus on DPX-0907","volume":"8","author":"M. Karkada","year":"2014","unstructured":"M. Karkada. Therapeutic vaccines and cancer: Focus on DPX-0907. 2014, 8: 27-38.","journal-title":"Biologics"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"2204335","DOI":"10.1002\/advs.202204335","article-title":"Targeted cancer immunotherapy: Nanoformulation engineering and clinical translation","volume":"9","author":"M. H. Yu","year":"2022","unstructured":"M. H. Yu. Targeted cancer immunotherapy: Nanoformulation engineering and clinical translation. 2022, 9: 2204335.","journal-title":"Adv. Sci."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of cancer nanomedicines\u2014lessons learned from successes and failures","volume":"52","author":"H. L. He","year":"2019","unstructured":"H. L. He. Survey of clinical translation of cancer nanomedicines\u2014lessons learned from successes and failures. 2019, 52: 2445-2461.","journal-title":"Acc. Chem. Res."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial","volume":"15","author":"C. Butts","year":"2014","unstructured":"C. Butts. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. 2014, 15: 59-68.","journal-title":"Lancet Oncol."},{"key":"ref101","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JCO.2017.35.6_suppl.30","article-title":"Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation","volume":"35","author":"R. A. Madan","year":"2017","unstructured":"R. A. Madan. Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation. 2017, 35: 30.","journal-title":"J. Clin. Oncol."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"e000612","DOI":"10.1136\/jitc-2020-000612","article-title":"Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine","volume":"8","author":"C. S. Rumfield","year":"2020","unstructured":"C. S. Rumfield. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. 2020, 8: e000612.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.4049\/jimmunol.1801634","article-title":"Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a type I IFN response","volume":"202","author":"S. K. Gandhapudi","year":"2019","unstructured":"S. K. Gandhapudi. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a type I IFN response. 2019, 202: 3524-3536.","journal-title":"J. Immunol."},{"key":"ref104","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.ijrobp.2021.12.087","article-title":"Preliminary safety of PDS0101 (Versamune+HPVmix) and pembrolizumab combination therapy in subjects with recurrent\/metastatic human papillomavirus-16 positive oropharyngeal squamous cell carcinoma (OPSCC)","volume":"112","author":"L. Wood","year":"2022","unstructured":"L. Wood. Preliminary safety of PDS0101 (Versamune+HPVmix) and pembrolizumab combination therapy in subjects with recurrent\/metastatic human papillomavirus-16 positive oropharyngeal squamous cell carcinoma (OPSCC). 2022, 112: e37-e38.","journal-title":"Int. J. Radiat. Oncol.*Biol.*Phys."},{"key":"ref105","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1016\/j.ijrobp.2024.07.205","article-title":"IMMUNOCERV phase II trial combining the HPV-specific T cell immunotherapy PDS0101 with chemoradiation for treatment of locally advanced cervical cancer","volume":"120","author":"A. Grippin","year":"2024","unstructured":"A. Grippin. IMMUNOCERV phase II trial combining the HPV-specific T cell immunotherapy PDS0101 with chemoradiation for treatment of locally advanced cervical cancer. 2024, 120: S113.","journal-title":"Int. J. Radiat. Oncol.*Biol.*Phys."},{"key":"ref106","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1200\/JCO.2023.41.16_suppl.6012","article-title":"Safety and efficacy of immune checkpoint inhibitor (ICI) na\u00efve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC)","volume":"41","author":"K. A. R. Price","year":"2023","unstructured":"K. A. R. Price. Safety and efficacy of immune checkpoint inhibitor (ICI) na\u00efve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC). 2023, 41: 6012.","journal-title":"J. Clin. Oncol."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"A704","DOI":"10.1136\/jitc-2022-SITC2022.0674","article-title":"674 IMMUNOCERV, an ongoing phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers","volume":"10","author":"K. Yoshida-Court","year":"2022","unstructured":"K. Yoshida-Court. 674 IMMUNOCERV, an ongoing phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers. 2022, 10: A704.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"9215","DOI":"10.3390\/cimb45110577","article-title":"Head and neck squamous cell carcinoma vaccine: Current landscape and perspectives","volume":"45","author":"P. G. Meliante","year":"2023","unstructured":"P. G. Meliante. Head and neck squamous cell carcinoma vaccine: Current landscape and perspectives. 2023, 45: 9215-9233.","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref111","doi-asserted-by":"publisher","first-page":"A797","DOI":"10.1136\/jitc-2022-SITC2022.0766","article-title":"766 Phase I\/II evaluation of the combination of entinostat, M9241 and bintrafusp alfa in patients with advanced HPV related malignancies","volume":"10","author":"J. Strauss","year":"2022","unstructured":"J. Strauss. 766 Phase I\/II evaluation of the combination of entinostat, M9241 and bintrafusp alfa in patients with advanced HPV related malignancies. 2022, 10: A797.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"101010","DOI":"10.1016\/j.esmoop.2023.101010","article-title":"44P HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy","volume":"8","author":"L. V. Wood","year":"2023","unstructured":"L. V. Wood. 44P HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy. 2023, 8: 101010.","journal-title":"ESMO Open"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"10114","DOI":"10.1021\/acs.nanolett.4c02196","article-title":"Uniform polymeric nanovaccine platform for improving the availability and efficacy of neoantigen peptides","volume":"24","author":"H. Y. Chen","year":"2024","unstructured":"H. Y. Chen. Uniform polymeric nanovaccine platform for improving the availability and efficacy of neoantigen peptides. 2024, 24: 10114-10123.","journal-title":"Nano Lett."},{"key":"ref114","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/vaccines9080935","article-title":"Advances in engineered polymer nanoparticle tracking platforms towards cancer immunotherapy\u2014current status and future perspectives","volume":"9","author":"R. Thangam","year":"2021","unstructured":"R. Thangam. Advances in engineered polymer nanoparticle tracking platforms towards cancer immunotherapy\u2014current status and future perspectives. 2021, 9: 935.","journal-title":"Vaccines"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00262-013-1499-2","article-title":"The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: A placebo-controlled phase II study","volume":"63","author":"P. J. De Vos Van Steenwijk","year":"2014","unstructured":"P. J. De Vos Van Steenwijk. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: A placebo-controlled phase II study. 2014, 63: 147-160.","journal-title":"Cancer Immunol., Immunother."},{"key":"ref116","doi-asserted-by":"publisher","first-page":"54399","DOI":"10.1021\/acsami.0c15522","article-title":"Employing ATP as a new adjuvant promotes the induction of robust antitumor cellular immunity by a PLGA nanoparticle vaccine","volume":"12","author":"Q. S. Zhang","year":"2020","unstructured":"Q. S. Zhang. Employing ATP as a new adjuvant promotes the induction of robust antitumor cellular immunity by a PLGA nanoparticle vaccine. 2020, 12: 54399-54414.","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41565-020-00782-3","article-title":"Proton-driven transformable nanovaccine for cancer immunotherapy","volume":"15","author":"N. Q. Gong","year":"2020","unstructured":"N. Q. Gong. Proton-driven transformable nanovaccine for cancer immunotherapy. 2020, 15: 1053-1064.","journal-title":"Nat. Nanotechnol."},{"key":"ref118","doi-asserted-by":"publisher","first-page":"e050725","DOI":"10.1136\/bmjopen-2021-050725","article-title":"Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: A first-in-human phase I open-label dose-escalation study protocol","volume":"11","author":"J. H. A. Creemers","year":"2021","unstructured":"J. H. A. Creemers. Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: A first-in-human phase I open-label dose-escalation study protocol. 2021, 11: e050725.","journal-title":"BMJ Open"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"1436968","DOI":"10.3389\/fimmu.2024.1436968","article-title":"Traversing the bench to bedside journey for iNKT cell therapies","volume":"15","author":"J. O\u2019Neal","year":"2024","unstructured":"J. O\u2019Neal. Traversing the bench to bedside journey for iNKT cell therapies. 2024, 15: 1436968.","journal-title":"Front. Immunol."},{"key":"ref120","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1021\/bc900290d","article-title":"Dendrimers for vaccine and immunostimulatory uses","volume":"21","author":"P. M. H. Heegaard","year":"2010","unstructured":"P. M. H. Heegaard. Dendrimers for vaccine and immunostimulatory uses. 2010, 21: 405-418.","journal-title":"A review. Bioconjug. Chem."},{"key":"ref121","doi-asserted-by":"publisher","first-page":"121303","DOI":"10.1016\/j.biomaterials.2021.121303","article-title":"Dendrimers in vaccine delivery: Recent progress and advances","volume":"280","author":"S. Chowdhury","year":"2022","unstructured":"S. Chowdhury. Dendrimers in vaccine delivery: Recent progress and advances. 2022, 280: 121303.","journal-title":"Biomaterials"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1038\/s41467-021-25197-z","article-title":"An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination","volume":"12","author":"Y. C. Wang","year":"2021","unstructured":"Y. C. Wang. An amphiphilic dendrimer as a light-activable immunological adjuvant for \n              in situ cancer vaccination. 2021, 12: 4964.","journal-title":"Nat. Commun."},{"key":"ref123","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1021\/bm400626w","article-title":"Self-adjuvanting polymer\u2013peptide conjugates as therapeutic vaccine candidates against cervical cancer","volume":"14","author":"T. Y. Liu","year":"2013","unstructured":"T. Y. Liu. Self-adjuvanting polymer\u2013peptide conjugates as therapeutic vaccine candidates against cervical cancer. 2013, 14: 2798-2806.","journal-title":"Biomacromolecules"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1016\/j.matt.2023.08.001","article-title":"A coordinative dendrimer-based nanovaccine for cancer treatment","volume":"6","author":"Z. Q. Cao","year":"2023","unstructured":"Z. Q. Cao. A coordinative dendrimer-based nanovaccine for cancer treatment. 2023, 6: 3574-3597.","journal-title":"Matter"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"2300116","DOI":"10.1002\/advs.202300116","article-title":"A Dendrimer Peptide (KK2DP7) Delivery System with dual functions of lymph node targeting and immune adjuvants as a general strategy for cancer immunotherapy","volume":"10","author":"R. Zhang","year":"2023","unstructured":"R. Zhang. A Dendrimer Peptide (KK2DP7) Delivery System with dual functions of lymph node targeting and immune adjuvants as a general strategy for cancer immunotherapy. 2023, 10: 2300116.","journal-title":"Adv. Sci."},{"key":"ref126","doi-asserted-by":"publisher","first-page":"13735","DOI":"10.1039\/D3RA01421E","article-title":"Organic and inorganic nanomaterials: Fabrication, properties and applications","volume":"13","author":"B. H. Alshammari","year":"2023","unstructured":"B. H. Alshammari. Organic and inorganic nanomaterials: Fabrication, properties and applications. 2023, 13: 13735-13785.","journal-title":"RSC Adv."},{"key":"ref127","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.addr.2012.08.015","article-title":"Surface engineering of inorganic nanoparticles for imaging and therapy","volume":"65","author":"J. Nam","year":"2013","unstructured":"J. Nam. Surface engineering of inorganic nanoparticles for imaging and therapy. 2013, 65: 622-648.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref128","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.progpolymsci.2013.02.003","article-title":"Surface modification of inorganic nanoparticles for development of organic\u2013inorganic nanocomposites\u2014a review","volume":"38","author":"S. Kango","year":"2013","unstructured":"S. Kango. Surface modification of inorganic nanoparticles for development of organic\u2013inorganic nanocomposites\u2014a review. 2013, 38: 1232-1261.","journal-title":"Prog. Polym. Sci."},{"key":"ref129","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1021\/acscentsci.8b00035","article-title":"Extra-large pore mesoporous silica nanoparticles enabling co-delivery of high amounts of protein antigen and toll-like receptor 9 agonist for enhanced cancer vaccine efficacy","volume":"4","author":"B. G. Cha","year":"2018","unstructured":"B. G. Cha. Extra-large pore mesoporous silica nanoparticles enabling co-delivery of high amounts of protein antigen and toll-like receptor 9 agonist for enhanced cancer vaccine efficacy. 2018, 4: 484-492.","journal-title":"ACS Cent. Sci."},{"key":"ref130","doi-asserted-by":"publisher","first-page":"352","DOI":"10.20892\/j.issn.2095-3941.2021.0004","article-title":"Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development","volume":"18","author":"J. Liang","year":"2021","unstructured":"J. Liang. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. 2021, 18: 352-371.","journal-title":"Cancer Biol. Med."},{"key":"ref131","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/acscentsci.8b00181","article-title":"Tailored silica nanomaterials for immunotherapy","volume":"4","author":"L. Gu","year":"2018","unstructured":"L. Gu. Tailored silica nanomaterials for immunotherapy. 2018, 4: 527-529.","journal-title":"ACS Cent. Sci."},{"key":"ref132","doi-asserted-by":"publisher","first-page":"2200756","DOI":"10.1002\/advs.202200756","article-title":"Mesoporous silica materials as an emerging tool for cancer immunotherapy","volume":"9","author":"B. Escriche-Navarro","year":"2022","unstructured":"B. Escriche-Navarro. Mesoporous silica materials as an emerging tool for cancer immunotherapy. 2022, 9: 2200756.","journal-title":"Adv. Sci."},{"key":"ref133","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3390\/pharmaceutics15072003","article-title":"Metal-based nanoparticles for cancer metalloimmunotherapy","volume":"15","author":"I. H. Suliman","year":"2023","unstructured":"I. H. Suliman. Metal-based nanoparticles for cancer metalloimmunotherapy. 2023, 15: 2003.","journal-title":"Pharmaceutics"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/pharmaceutics14020435","article-title":"Recent developments in metallic nanomaterials for cancer therapy, diagnosing and imaging applications","volume":"14","author":"D. N. P\u0103duraru","year":"2022","unstructured":"D. N. P\u0103duraru. Recent developments in metallic nanomaterials for cancer therapy, diagnosing and imaging applications. 2022, 14: 435.","journal-title":"Pharmaceutics"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"119859","DOI":"10.1016\/j.biomaterials.2020.119859","article-title":"Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen\/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold","volume":"239","author":"T. L. Nguyen","year":"2020","unstructured":"T. L. Nguyen. Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen\/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold. 2020, 239: 119859.","journal-title":"Biomaterials"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41563-018-0028-2","article-title":"A facile approach to enhance antigen response for personalized cancer vaccination","volume":"17","author":"A. W. Li","year":"2018","unstructured":"A. W. Li. A facile approach to enhance antigen response for personalized cancer vaccination. 2018, 17: 528-534.","journal-title":"Nat. Mater."},{"key":"ref137","doi-asserted-by":"publisher","first-page":"eaaz4462","DOI":"10.1126\/sciadv.aaz4462","article-title":"The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency","volume":"6","author":"X. Y. Hong","year":"2020","unstructured":"X. Y. Hong. The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency. 2020, 6: eaaz4462.","journal-title":"Sci. Adv."},{"key":"ref138","doi-asserted-by":"publisher","first-page":"47798","DOI":"10.1021\/acsami.9b19446","article-title":"Polyethylenimine hybrid thin-shell hollow mesoporous silica nanoparticles as vaccine self-adjuvants for cancer immunotherapy","volume":"11","author":"Q. Q. Liu","year":"2019","unstructured":"Q. Q. Liu. Polyethylenimine hybrid thin-shell hollow mesoporous silica nanoparticles as vaccine self-adjuvants for cancer immunotherapy. 2019, 11: 47798-47809.","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.actbio.2022.04.001","article-title":"Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site","volume":"145","author":"X. P. Wang","year":"2022","unstructured":"X. P. Wang. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site. 2022, 145: 235-245.","journal-title":"Acta Biomater."},{"key":"ref140","doi-asserted-by":"publisher","first-page":"1701741","DOI":"10.1002\/smll.201701741","article-title":"Encapsulation of hydrophilic and hydrophobic peptides into hollow mesoporous silica nanoparticles for enhancement of antitumor immune response","volume":"13","author":"J. Xie","year":"2017","unstructured":"J. Xie. Encapsulation of hydrophilic and hydrophobic peptides into hollow mesoporous silica nanoparticles for enhancement of antitumor immune response. 2017, 13: 1701741.","journal-title":"Small"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12935-023-03115-1","article-title":"Metal nanoparticles as a potential technique for the diagnosis and treatment of gastrointestinal cancer: A comprehensive review","volume":"23","author":"M. Roshani","year":"2023","unstructured":"M. Roshani. Metal nanoparticles as a potential technique for the diagnosis and treatment of gastrointestinal cancer: A comprehensive review. 2023, 23: 280.","journal-title":"Cancer Cell Int."},{"key":"ref142","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12943-023-01798-8","article-title":"Gold nanoparticles and gold nanorods in the landscape of cancer therapy","volume":"22","author":"P. Kesharwani","year":"2023","unstructured":"P. Kesharwani. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. 2023, 22: 98.","journal-title":"Mol. Cancer"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12951-024-02311-z","article-title":"The quest for nanoparticle-powered vaccines in cancer immunotherapy","volume":"22","author":"Z. Sun","year":"2024","unstructured":"Z. Sun. The quest for nanoparticle-powered vaccines in cancer immunotherapy. 2024, 22: 61.","journal-title":"J. Nanobiotechnol."},{"key":"ref144","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/smll.201402179","article-title":"In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models","volume":"11","author":"J. P. M. Almeida","year":"2015","unstructured":"J. P. M. Almeida. \n              In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. 2015, 11: 1453-1459.","journal-title":"Small"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.cclet.2019.10.015","article-title":"Non-covalent glycosylated gold nanoparticles\/peptides nanovaccine as potential cancer vaccines","volume":"31","author":"L. M. Zeng","year":"2020","unstructured":"L. M. Zeng. Non-covalent glycosylated gold nanoparticles\/peptides nanovaccine as potential cancer vaccines. 2020, 31: 1162-1164.","journal-title":"Chin. Chem. Lett."},{"key":"ref146","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2022.09.015","article-title":"Lymph node-targeting nanovaccines for cancer immunotherapy","volume":"351","author":"Q. Wang","year":"2022","unstructured":"Q. Wang. Lymph node-targeting nanovaccines for cancer immunotherapy. 2022, 351: 102-122.","journal-title":"J. Control. Release"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.bbrc.2020.11.047","article-title":"Oral intake of silica nanoparticles exacerbates intestinal inflammation","volume":"534","author":"T. Ogawa","year":"2021","unstructured":"T. Ogawa. Oral intake of silica nanoparticles exacerbates intestinal inflammation. 2021, 534: 540-546.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref148","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1002\/mco2.327","article-title":"Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models","volume":"4","author":"L. H. Xuan","year":"2023","unstructured":"L. H. Xuan. Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. 2023, 4: e327.","journal-title":"MedComm"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/cr.2015.9","article-title":"Cationic nanocarriers induce cell necrosis through impairment of Na+\/K+-ATPase and cause subsequent inflammatory response","volume":"25","author":"X. W. Wei","year":"2015","unstructured":"X. W. Wei. Cationic nanocarriers induce cell necrosis through impairment of Na\n              +\/K\n              +-ATPase and cause subsequent inflammatory response. 2015, 25: 237-253.","journal-title":"Cell Res."},{"key":"ref150","doi-asserted-by":"publisher","first-page":"114932","DOI":"10.1016\/j.taap.2020.114932","article-title":"Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation","volume":"392","author":"J. K. Simmons","year":"2020","unstructured":"J. K. Simmons. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation. 2020, 392: 114932.","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref151","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jconrel.2019.09.020","article-title":"Optimizing biodegradable nanoparticle size for tissue-specific delivery","volume":"314","author":"H. K. Mandl","year":"2019","unstructured":"H. K. Mandl. Optimizing biodegradable nanoparticle size for tissue-specific delivery. 2019, 314: 92-101.","journal-title":"J. Control. Release"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41529-022-00277-7","article-title":"Recent advances in biodegradable polymers for sustainable applications","volume":"6","author":"A. Samir","year":"2022","unstructured":"A. Samir. Recent advances in biodegradable polymers for sustainable applications. 2022, 6: 68.","journal-title":"npj Mater. Degrad."},{"key":"ref153","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1477-3155-9-55","article-title":"Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines","volume":"9","author":"A. Mahapatro","year":"2011","unstructured":"A. Mahapatro. Biodegradable nanoparticles are excellent vehicle for site directed \n              in-\n              vivo delivery of drugs and vaccines. 2011, 9: 55.","journal-title":"J. Nanobiotechnol."},{"key":"ref154","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"B. L. Wang","year":"2024","unstructured":"B. L. Wang. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. 2024, 9: 200.","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref155","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1479-5876-10-156","article-title":"First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients","volume":"10","author":"N. L. Berinstein","year":"2012","unstructured":"N. L. Berinstein. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. 2012, 10: 156.","journal-title":"J. Transl. Med."},{"key":"ref156","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1158\/1538-7445.AM2011-762","article-title":"ONT-10, a liposomal vaccine targeting hypoglycosylated MUC1, induces a potent cellular and humoral response and suppresses the growth of MUC1 expressing tumors","volume":"71","author":"L. A. Pestano","year":"2011","unstructured":"L. A. Pestano. ONT-10, a liposomal vaccine targeting hypoglycosylated MUC1, induces a potent cellular and humoral response and suppresses the growth of MUC1 expressing tumors. 2011, 71: 762.","journal-title":"Cancer Res."},{"key":"ref157","doi-asserted-by":"publisher","first-page":"P240","DOI":"10.1186\/2051-1426-1-S1-P240","article-title":"Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer","volume":"1","author":"J. Nemunaitis","year":"2013","unstructured":"J. Nemunaitis. Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer. 2013, 1: P240.","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/jco.2014.32.15_suppl.3091","article-title":"Tolerability, humoral immune response, and disease control in phase 1 patients receiving ONT-10, a MUC1 liposomal vaccine","volume":"32","author":"J. J. Nemunaitis","year":"2014","unstructured":"J. J. Nemunaitis. Tolerability, humoral immune response, and disease control in phase 1 patients receiving ONT-10, a MUC1 liposomal vaccine. 2014, 32: 3091.","journal-title":"J. Clin. Oncol."},{"key":"ref159","doi-asserted-by":"publisher","first-page":"s4652","DOI":"10.1158\/1078-0432.CCR-07-0213","article-title":"L-BLP25: A peptide vaccine strategy in non small cell lung cancer","volume":"13","author":"R. Sangha","year":"2007","unstructured":"R. Sangha. L-BLP25: A peptide vaccine strategy in non small cell lung cancer. 2007, 13: s4652-s4654.","journal-title":"Clin. Cancer Res."},{"key":"ref160","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/annonc\/mdv104","article-title":"Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses","volume":"26","author":"P. Mitchell","year":"2015","unstructured":"P. Mitchell. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses. 2015, 26: 1134-1142.","journal-title":"Ann. Oncol."},{"key":"ref161","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/1471-2407-11-430","article-title":"INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer","volume":"11","author":"Y. L. Wu","year":"2011","unstructured":"Y. L. Wu. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. 2011, 11: 430.","journal-title":"BMC Cancer"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1200\/jco.2013.31.15_suppl.7500","article-title":"START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer","volume":"31","author":"C. A. Butts","year":"2013","unstructured":"C. A. Butts. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. 2013, 31: 7500.","journal-title":"J. Clin. Oncol."},{"key":"ref163","doi-asserted-by":"publisher","first-page":"2292940","DOI":"10.1080\/21645515.2023.2292940","article-title":"Human vaccines & immunotherapeutics: News November 2023","volume":"19","author":"R. Ellis","year":"2023","unstructured":"R. Ellis. Human vaccines & immunotherapeutics: News November 2023. 2023, 19: 2292940.","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref164","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2020.07.016","article-title":"Opportunities and challenges in commercial pharmaceutical liposome applications","volume":"154\u2013155","author":"G. M. Jensen","year":"2020","unstructured":"G. M. Jensen. Opportunities and challenges in commercial pharmaceutical liposome applications. 2020, 154\u2013155: 2-12.","journal-title":"Adv. Drug Delivery Rev."},{"key":"ref165","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cct.2010.03.005","article-title":"Automated matching software for clinical trials eligibility: Measuring efficiency and flexibility","volume":"31","author":"L. Penberthy","year":"2010","unstructured":"L. Penberthy. Automated matching software for clinical trials eligibility: Measuring efficiency and flexibility. 2010, 31: 207-217.","journal-title":"Contemp. Clin. Trials"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12874-023-01916-6","article-title":"Piloting an automated clinical trial eligibility surveillance and provider alert system based on artificial intelligence and standard data models","volume":"23","author":"S. M. Meystre","year":"2023","unstructured":"S. M. Meystre. Piloting an automated clinical trial eligibility surveillance and provider alert system based on artificial intelligence and standard data models. 2023, 23: 88.","journal-title":"BMC Med. Res. Methodol."},{"key":"ref167","first-page":"1","article-title":"Automating data entry from electronic health record to electronic data capture using trusted cloud-based application in multisite cancer clinical trials","volume":"6","author":"K. Goodman","year":"2025","unstructured":"K. Goodman. Automating data entry from electronic health record to electronic data capture using trusted cloud-based application in multisite cancer clinical trials. 2025, 6: 1.","journal-title":"J. Soc. Clin. Data Manage."},{"key":"ref168","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s13063-017-2099-9","article-title":"Barriers to the conduct of randomised clinical trials within all disease areas","volume":"18","author":"S. Djurisic","year":"2017","unstructured":"S. Djurisic. Barriers to the conduct of randomised clinical trials within all disease areas. 2017, 18: 360.","journal-title":"Trials"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"1903847","DOI":"10.1002\/adma.201903847","article-title":"Immunology-guided biomaterial design for mucosal cancer vaccines","volume":"32","author":"S. Ferber","year":"2020","unstructured":"S. Ferber. Immunology-guided biomaterial design for mucosal cancer vaccines. 2020, 32: 1903847.","journal-title":"Adv. Mater."},{"key":"ref170","doi-asserted-by":"publisher","first-page":"e23510","DOI":"10.4161\/onci.23510","article-title":"Trial watch: Chemotherapy with immunogenic cell death inducers","volume":"2","author":"E. Vacchelli","year":"2013","unstructured":"E. Vacchelli. Trial watch: Chemotherapy with immunogenic cell death inducers. 2013, 2: e23510.","journal-title":"Oncoimmunology"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-21167-1_1","author":"","unstructured":"","journal-title":"null"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.4161\/hv.29918","article-title":"Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study","volume":"10","author":"E. Rossmann","year":"2014","unstructured":"E. Rossmann. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study. 2014, 10: 3394-3408.","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref173","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2019.37.4_suppl.571","article-title":"Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3)","volume":"37","author":"M. H. Moehler","year":"2019","unstructured":"M. H. Moehler. Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3). 2019, 37: 571.","journal-title":"J. Clin. Oncol."},{"key":"ref174","doi-asserted-by":"publisher","first-page":"1900101","DOI":"10.1002\/advs.201900101","article-title":"Immunomodulatory nanosystems","volume":"6","author":"X. R. Feng","year":"2019","unstructured":"X. R. Feng. Immunomodulatory nanosystems. 2019, 6: 1900101.","journal-title":"Adv. Sci."},{"key":"ref175","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jtho.2019.03.022","article-title":"Advanced-stage non\u2013small cell lung cancer: Advances in thoracic oncology 2018","volume":"14","author":"J. Remon","year":"2019","unstructured":"J. Remon. Advanced-stage non\u2013small cell lung cancer: Advances in thoracic oncology 2018. 2019, 14: 1134-1155.","journal-title":"J. Thorac. Oncol."},{"key":"ref176","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.3747\/co.v18i1.623","article-title":"Immune therapy for breast cancer in 2010\u2014hype or hope","volume":"18","author":"A. Florescu","year":"2011","unstructured":"A. Florescu. Immune therapy for breast cancer in 2010\u2014hype or hope. 2011, 18: e9-e18.","journal-title":"Curr. Oncol."},{"key":"ref177","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1078-0432.CCR-14-1187","article-title":"Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer","volume":"21","author":"V. K. Anagnostou","year":"2015","unstructured":"V. K. Anagnostou. Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer. 2015, 21: 976-984.","journal-title":"Clin. Cancer Res."},{"key":"ref178","doi-asserted-by":"publisher","first-page":"e29030","DOI":"10.4161\/onci.29030","article-title":"Trial watch: Immunostimulatory cytokines in cancer therapy","volume":"3","author":"E. Vacchelli","year":"2014","unstructured":"E. Vacchelli. Trial watch: Immunostimulatory cytokines in cancer therapy. 2014, 3: e29030.","journal-title":"Oncoimmunology"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-11-246","article-title":"Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients","volume":"11","author":"S. Kageyama","year":"2013","unstructured":"S. Kageyama. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. 2013, 11: 1-10.","journal-title":"J. Transl. Med."},{"key":"ref180","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","article-title":"Current approaches of nanomedicines in the market and various stage of clinical translation","volume":"12","author":"X. T. Shan","year":"2022","unstructured":"X. T. Shan. Current approaches of nanomedicines in the market and various stage of clinical translation. 2022, 12: 3028-3048.","journal-title":"Acta Pharm. Sin. B"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/17425247.2018.1504768","article-title":"Quality by design (QbD) approaches in current pharmaceutical set-up","volume":"15","author":"V. Mishra","year":"2018","unstructured":"V. Mishra. Quality by design (QbD) approaches in current pharmaceutical set-up. 2018, 15: 737-758.","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref182","doi-asserted-by":"publisher","first-page":"27953","DOI":"10.1021\/acsomega.3c02030","article-title":"Nanoadjuvants: Promising bioinspired and biomimetic approaches in vaccine innovation","volume":"8","author":"D. N. Desai","year":"2023","unstructured":"D. N. Desai. Nanoadjuvants: Promising bioinspired and biomimetic approaches in vaccine innovation. 2023, 8: 27953-27968.","journal-title":"ACS Omega"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-817778-5.00007-5","author":"","unstructured":"","journal-title":"null"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.addr.2017.08.003","article-title":"Current developments and applications of microfluidic technology toward clinical translation of nanomedicines","volume":"128","author":"D. F. Liu","year":"2018","unstructured":"D. F. Liu. Current developments and applications of microfluidic technology toward clinical translation of nanomedicines. 2018, 128: 54-83.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref185","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jconrel.2016.07.019","article-title":"Co-opting Moore's law: Therapeutics, vaccines and interfacially active particles manufactured via PRINT\u00ae","volume":"240","author":"J. M. Desimone","year":"2016","unstructured":"J. M. Desimone. Co-opting Moore's law: Therapeutics, vaccines and interfacially active particles manufactured via PRINT\u00ae. 2016, 240: 541-543.","journal-title":"J. Control. Release"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"20.1.1","DOI":"10.1002\/0471142735.im2001s108","article-title":"Mouse model for Pre-Clinical study of human cancer immunotherapy","volume":"108","author":"Z. Y. Ya","year":"2015","unstructured":"Z. Y. Ya. Mouse model for Pre-Clinical study of human cancer immunotherapy. 2015, 108: 20.1.1-20.1.43.","journal-title":"Curr. Protoc. Immunol."},{"key":"ref187","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41565-021-00950-z","article-title":"Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy","volume":"16","author":"Z. R. Wang","year":"2021","unstructured":"Z. R. Wang. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. 2021, 16: 1130-1140.","journal-title":"Nat. Nanotechnol."},{"key":"ref188","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1158\/0008-5472.CAN-11-2786","article-title":"Genetically engineered mouse models: Closing the gap between preclinical data and trial outcomes","volume":"72","author":"M. Singh","year":"2012","unstructured":"M. Singh. Genetically engineered mouse models: Closing the gap between preclinical data and trial outcomes. 2012, 72: 2695-2700.","journal-title":"Cancer Res."},{"key":"ref189","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41586-021-03512-4","article-title":"AI-based pathology predicts origins for cancers of unknown primary","volume":"594","author":"M. Y. Lu","year":"2021","unstructured":"M. Y. Lu. AI-based pathology predicts origins for cancers of unknown primary. 2021, 594: 106-110.","journal-title":"Nature"},{"key":"ref190","doi-asserted-by":"publisher","first-page":"19997","DOI":"10.1073\/pnas.1009010107","article-title":"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer","volume":"107","author":"F. Su","year":"2010","unstructured":"F. Su. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. 2010, 107: 19997-20002.","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nano Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:33:05Z","timestamp":1750120385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/NR.2025.94907534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":187,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.26599\/nr.2025.94907534","relation":{},"ISSN":["1998-0124","1998-0000"],"issn-type":[{"value":"1998-0124","type":"print"},{"value":"1998-0000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}